Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2007

Zapata M, Cohen C, Siddiqui MT. Immunohistochemical expression of SMAD4, CK19, and CA19-9 in fine needle aspiration samples of pancreatic adenocarcinoma: Utility and potential role. Cytojournal. 2007;4:13.

Pidcoke HF, Salinas J, Wanek SM, Concannon M, Loo F, Wirfel KL, et al. Patterns of exogenous insulin requirement reflect insulin sensitivity changes in trauma. Am J Surg. 2007;194(6):798-803; discussion 803.

Bhalla R, Siddiqui MT, Mandich D, Cartun RW, Fiel-Gan MD, Nassar A, et al. Diagnostic utility of D2-40 and podoplanin in effusion cell blocks. Diagn Cytopathol. 2007;35(6):342-7.

Heymann JJ, Benson MC, O'Toole KM, Malyszko B, Brody R, Vecchio D, et al. Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer. J Clin Oncol. 2007;25(1):77-84.

Jaggi JS, Henke E, Seshan SV, Kappel BJ, Chattopadhyay D, May C, et al. Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization. PLoS One. 2007;2(3):e267.

Ogino S, Kawasaki T, Kirkner GJ, Kraft P, Loda M, Fuchs CS. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn. 2007;9(3):305-14.

Cang Y, Zhang J, Nicholas SA, Kim AL, Zhou P, Goff SP. DDB1 is essential for genomic stability in developing epidermis. Proc Natl Acad Sci U S A. 2007;104(8):2733-7.

Yang C, Jo S-, Csernus B, Hyjek E, Liu Y, Chadburn A, et al. Activation of peroxisome proliferator-activated receptor gamma contributes to the survival of T lymphoma cells by affecting cellular metabolism. Am J Pathol. 2007;170(2):722-32.

M Lensch W, Ince TA. The terminology of teratocarcinomas and teratomas. Nat Biotechnol. 2007;25(11):1211; author reply 1211-2.

Marchionni L, Wilson RF, Marinopoulos SS, Wolff AC, Parmigiani G, Bass EB, et al. Impact of gene expression profiling tests on breast cancer outcomes. Evid Rep Technol Assess (Full Rep). 2007;(160):1-105.